Articles about 'David Tuveson'

A multi-disciplinary centre of excellence which aims to bring cutting-edge pancreatic research from the bench to the bedside is launched.

Can better decisions be made about which anticancer drugs to progress to clinical trials?

An international team of scientists, led by researchers based at the Cambridge Research Institute, have discovered a new mechanism that may explain why pancreatic cancer patients are often resistant to a common chemotherapy treatment, germcitabine.

The Cambridge Research Institute (CRI) is driving the development of new approaches for the early detection, prevention and treatment of cancer.